Chromatin regulation in drug addiction and depression by Renthal, William & Nestler, Eric J.
amily history is one of the greatest risk factors
for psychiatric disorders, yet their genetic basis remains
poorly understood despite substantial advances in whole
genome sequencing techniques. While the search for
genetic mutations continues at a rapid pace, the field is
also investigating the environmental component of fam-
ily history, which has remained more difficult to explain
mechanistically. One hypothesis is that environmental
stimuli alter gene expression patterns in certain brain
regions that ultimately change neural function and
behavior. Support for this hypothesis has been observed
in animal models of psychiatric illness, as well as in
human patients. 
The interactions between the environment and the genes
that give rise to specific phenotypes are termed “epige-
netic.”
1 An example of this process is observed in cellu-
lar differentiation, where unique chemical signals induce
totipotent stem cells to differentiate into genetically
identical cell types with vastly different functions. This is
due in part to the vastly different sets of genes expressed
between distinct cell types (eg, neurons vs hepatocytes),
despite their identical DNA templates. Mechanistic
insight into this process has recently been uncovered,
and involves the transduction of unique environmental
signals into precise and highly stable alterations in chro-
matin structure that ultimately gate access of transcrip-
tional machinery to specific gene programs, thereby pro-
viding unique gene expression profiles in response to
specific environmental cues.
2 Importantly, many of these
chromatin remodeling mechanisms are highly stable,
contributing to the maintenance of specific gene expres-
sion programs in the correct tissues throughout the life
of an individual. 
The strong control exerted by chromatin remodeling on
gene expression, and the potential stability of chromatin
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Alterations in gene expression are implicated in the
pathogenesis of several neuropsychiatric disorders,
including drug addiction and depression. Increasing evi-
dence indicates that changes in gene expression in neu-
rons, in the context of animal models of addiction and
depression, are mediated in part by epigenetic mecha-
nisms that alter chromatin structure on specific gene pro-
moters. This review discusses recent findings from behav-
ioral, molecular, and bioinformatic approaches that are
being used to understand the complex epigenetic regu-
lation of gene expression in brain by drugs of abuse and
by stress. These advances promise to open up new
avenues for improved treatments of these disorders.
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:257-268.
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date for mediating aspects of the long-lasting neural
plasticity that ultimately results in psychiatric syndromes.
It is also interesting to note that certain neurological and
psychiatric diseases are caused by rare genetic mutations
in chromatin remodeling enzymes (Table I). While these
mutations are rare, they directly illustrate how disrup-
tion of chromatin regulation can profoundly affect
neural function and lead to complex behavioral abnor-
malities. Thus, epigenetic research in psychiatry is aimed
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Selected abbreviations and acronyms
BDNF brain derived neurotrophic factor
cAMP cyclic adenosine monophosphate
CREB cAMP-response element binding protein
H histone
HAT histone acetyltransferase
HDAC histone deacetylase
HDM histone demethylases
HMT histone methyltransferase
Disease Chromatin defect Clinical features
Rubinstein-Taybi syndrome Heterozygous mutations in CBP Autosomal dominant inheritance
Mental retardation
Abnormal facial features, blunted growth
Fragile X syndrome Hypermethylation of DNA at the FMR1 and  X-linked inheritance
FMR2 (Fragile X mental retardation-1,2)  Most common inherited form of mental
promoters, caused by trinucleotide repeat expansion retardation, signs of autistic behavior
Macrocephaly, long and narrow face with large ears, 
macro-orchidism, hypotonia
Coffin-Lowry syndrome Mutation in RSK2 (ribosomal S6 kinase-2), which can  X-linked inheritance
interact with CREB and CBP and can phosphorylate  Psychomotor retardation
H3 in vitro Craniofacial and skeletal abnormalities
Rett syndrome Mutations in MeCP2 X-linked, affecting predominantly girls
Pervasive developmental disorder associated with 
arrested brain development, cognitive decline, 
and autistic-like behavior
Alpha-thalassemia/mental Mutations in ATRX gene, encoding the X-linked X-linked inheritance
retardation syndrome, helicase-2 (XH2) – a member of SWI/SNF family of Mental retardation
X-linked (ATR-X) proteins Hemolytic anemia, splenomegaly, facial, skeletal,
Defective chromatin remodeling thought to  and genital anomalies
downregulate the α-globin locus
Immunodeficiency–centromeric Mutations in Dnmt3B Autosomal recessive
instability–facial anomalies Hypomethylation at centromeric regions Mild mental retardation
syndrome (ICF) of chromosomes 1, 9, and 16 Marked immunodeficiency, facial anomalies
Myotonic dystrophy Abnormal CTG repeat expansion at the 3’UTR of the  Autosomal dominant
DM1-Protein Kinase gene favors chromatin  Mild mental retardation, myotonia, abnormal 
condensation, affecting expression of many  cardiac conduction, insulin-dependent diabetes,
neighboring genes testicular atrophy, premature balding
Prader-Willi syndrome Imprinting (DNA methylation) of maternal  Imprinting+mutation
chromosomal region 15q11-13 Mild mental retardation, endocrine abnormalities
Angelman syndrome Imprinting (DNA methylation) of paternal  Imprinting+mutation
chromosomal region 15q11-13 Cortical atrophy, cerebellar dysmyelination, 
cognitive abnormalities
Table I. Examples of diseases of chromatin remodeling. CBP, CREB binding protein; CREB, cyclic AMP-response element binding protein; DMPK,
DM1 protein kinase; Dnmt3B, DNA methyltransferase 3B; FMR1, fragile X mental retardation protein 1; MeCP2, methyl-CpG-binding pro-
tein 2; RSK2, ribosomal S6 kinase 2; SWI/SNF, mating switching and sucrose non-fermenting complex; UTR, untranslated region; XH2, X-
linked helicase 2
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changes in chromatin structure which ultimately con-
tribute to transcriptional programs in neurons that cause
psychiatric illness, much in the same way as environ-
mental cues differentiate a stem cell into specific lin-
eages. While this field is still in its infancy, great progress
is being made in identifying epigenetic alterations in
many neuropsychiatric syndromes, including drug addic-
tion, depression, schizophrenia, Alzheimer’s disease, and
Rett syndrome, among others. Focusing on drug addic-
tion and depression, this review briefly discusses the
molecular machinery underlying epigenetic mechanisms
in brain, and how their dysregulation may contribute to
these chronic psychiatric illnesses. 
Epigenetic mechanisms
Chromatin is the complex of DNA, histones, and associ-
ated nonhistone proteins in the cell nucleus. DNA wraps
around histone octamers made up of two copies of his-
tone H2A, H2B, H3, and H4,
3 which then supercoil to
form a highly condensed structure (Figure 1). Initially, it
was thought that this elaborate chromatin structure only
functioned to condense meters of DNA into the micro-
scopic cell nucleus, but it is now known to participate
directly in gene regulation. Because DNA is tightly asso-
ciated with histones and often embedded deep within
chromatin supercoils,
4,5 cellular mechanisms exist to
modify and remodel chromatin structure to allow for the
coordinated expression of specific transcriptional pro-
grams and the silencing of others.
6 Such modifications
typically occur on N-terminal histone tails and include
acetylation, phosphorylation, methylation, or several
other covalent modifications of histones, methylation of
DNA, and many others, with each modification either
directly altering histone-DNA interactions or serving as
a mark that recruits specific proteins to positively or neg-
atively regulate the underlying gene’s activity.
Ultimately, dozens of potential modifications that occur
at many distinct histone residues summate to determine
the final transcriptional output of a given gene.
7As men-
tioned earlier, genetic mutations in many of these chro-
matin remodeling enzymes are associated with severe
neurological and psychiatric disorders (see Table I). An
especially important aspect of certain chromatin modi-
fications is their apparent stability, as is seen with genetic
imprinting or X-inactivation, where DNA methylation
contributes to lifelong gene silencing.
8 However, despite
the apparent stability of some epigenetic mechanisms in
vivo, all types of chromatin modifications identified to
date are potentially reversible and have specific enzymes
or processes which mediate the addition or removal of
each mark.
6The in vivo mechanisms which maintain eas-
ily reversible histone modifications (eg, acetylation) on
some genes or delete highly stable marks (eg, DNA
methylation) on other genes are currently not clear.
Histone acetylation 
Acetylation of histone lysine residues reduces the elec-
trostatic interaction between histone proteins and DNA,
which relaxes chromatin structure and improves access
of transcriptional regulators to DNA (Figure 1).
6
Genome-wide studies indicate that high levels of histone
acetylation in gene promoter regions are generally asso-
ciated with higher gene activity, while low levels of acety-
lation correlating with reduced gene activity.
9 Most
genome-wide studies of histone acetylation have focused
on acetylation of the N-terminal lysine residues in his-
tones H3 and H4, but histone acetylation can occur on
other histone proteins as well as in their globular
domains. 
Histone acetylation is a dynamic process, controlled by
specific enzymes which either add or remove the acetyl
mark. There are over a dozen known histone acetyl-
transferases (HATs) which catalyze the addition of
acetyl groups onto lysine residues of histones with vary-
ing degrees of specificity. Many HATs can also acetylate
nonhistone proteins such as transcription factors (eg,
p53), and some transcription factors (eg, ATF2 [activat-
ing transcription factor 2], CLOCK) even possess intrin-
sic HAT activity that contributes to gene activation.
10,11
Histone deacetylases (HDACs), which remove acetyl
groups from histones, are divided into four classes. Class
I HDACs (eg, HDAC1, 2, 3, and 8) are ubiquitously
expressed and likely mediate the majority of deacetylase
activity within cells. Class II HDACs (eg, HDAC4, 5, 7,
9, 10) are only expressed in specific tissues such as heart
and brain and are much larger enzymes that also contain
an N-terminal regulatory domain that enables them to
be shuttled in and out of the nucleus in a neural activity-
dependent manner.
12 While Class II HDACs can
deacetylate histones, they are much less efficient
enzymes than Class I HDACs, and may also deacetylate
other cellular substrates.
13,14There is currently one Class
IV HDAC, HDAC11, and it has characteristics of both
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15 Class III HDACs (also
referred to as sirtuins) are mechanistically distinct from
the other HDACs, and have been implicated in the reg-
ulation of lifespan and metabolism.
16 The individual
functions of each HDAC remain an active topic of inves-
tigation.
Histone phosphorylation 
Histone phosphorylation is generally associated with
transcriptional activation; it can be observed on the pro-
moters of immediate early genes such as c-fos when they
are induced after cyclic adenosine monophosphate
(cAMP) stimulation or glutamate treatment in cultured
striatal neurons.
17,18 One of the best-characterized histone
phosphorylation sites is serine 10 on histone H3
(H3S10). This modification stabilizes the HAT, GCN5,
on associated gene promoters while antagonizing the
repressive modification—methylation of lysine 9 on his-
tone H3 (H3K9) and its subsequent recruitment of HP1
(heterochromatin protein 1, see below).
6 Since phos-
phorylation at H3S10 recruits a HAT, the neighboring
lysine residue at H3K9 is often acetylated in concert
with phosphorylation, a process called phosphoacetyla-
tion that further potentiates gene activation. 
There are several nuclear protein kinases and protein
phosphatases known to regulate histone phosphoryla-
tion.
6The mitogen-activated protein kinase, MSK1, and
the dopamine and cyclic-AMP regulated protein phos-
phatase inhibitor, DARRP-32, are elegant examples
shown to regulate H3S10 phosphorylation in the adult
brain in response to cocaine exposure.
19,20 Furthermore,
genetic disruption of the histone-modifying ability of
MSK1 or DARRP-32 in vivo has dramatic effects on
behavioral responses to cocaine. Thus, histone phospho-
rylation likely plays an important role in the regulation
of brain function. 
Histone methylation
Histone methylation generates unique docking sites that
recruit transcriptional regulators to specific gene loci.
Histone methylation occurs on lysine residues in mono-,
di-, or trimethylated states, enabling each state to recruit
unique coregulators and exert distinct effects on tran-
scriptional activity.
6 Additionally, methylation of differ-
ent histone lysine residues can exert opposite effects on
transcription. In gene promoter regions for example,
trimethylation of H3K4 is highly associated with gene
activation, whereas trimethylation of H3K9 or H3K27 is
repressive.
5 The repression caused by trimethylation of
H3K9 is mediated in part via the recruitment of core-
pressors, such as HP1, as stated earlier. However, even
this is an oversimplification, as methylated H3K9 is often
found in the coding region downstream of a gene pro-
moter and may be involved in transcriptional elonga-
tion.
6,21Thus, histone methylation provides each cell with
exquisite control over an individual gene’s activity
through numerous combinatorial possibilities.
Histone methyltransferases (HMTs) add methyl groups
to specific lysine residues of histones, and histone
demethylases (HDMs) remove them (Figure 1). Like
HATs and HDACs, HMTs and HDMs also have activ-
ity towards nonhistone proteins.
6 HMTs and HDMs not
only discriminate between various histone lysine
residues, but each enzyme is also unique in its ability to
catalyze mono-, di-, or trimethylation or demethylation
at that site.
6 For example, the HMT, KMT1C (G9a), is
specific for histone H3K9 but only adds 1 or 2 methyl
groups, with the distinct HMT, KMT1A (SUV39H1),
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Figure 1. Chromatin remodeling. A. Picture of a nucleosome showing a DNA strand wrapped around a histone octamer composed of two copies each
of the histones H2A, H2B, H3 and H4. The amino (N) termini of the histones face outward from the nucleosome complex. B. Chromatin
can be conceptualized as existing in two primary structural states: as active, or open, euchromatin (top left) in which histone acetylation (A)
is associated with opening the nucleosome to allow binding of the basal transcriptional complex and other activators of transcription; or as
inactive, or condensed, heterochromatin where all gene activity is permanently silenced (bottom left). In reality, chromatin exists in a contin-
uum of functional states in between (eg, active; permissive (top right); repressed (bottom right); and inactive). Enrichment of histone modi-
fications such as acetylation and methylation (M) at histone N-terminal tails and related binding of transcription factors and coactivators (Co-
Act) or repressors (Rep) to chromatin modulates the transcriptional state of the nucleosome. Recent evidence suggests that inactivated chromatin
may in some cases be subject to reactivation in adult nerve cells, although this remains uncertain. C. Summary of common covalent modifi-
cations of H3, which include acetylation, methylation, and phosphorylation (P) at several amino acid residues. H3 phosphoacetylation com-
monly involves phosphorylation of S10 and acetylation of K14. Acetylation of lysine residues is catalysed by histone acetyltransferases (HATs)
and reversed by histone deacetylases (HDACs); lysine methylation (which can be either activating or repressing) is catalyzed by histone methyl-
transferases (HMTs) and reversed by histone demethylases (HDMs); and phosphorylation is catalysed by protein kinases (PK) and reversed by
protein phosphatases (PP), which have not yet been identified with certainty. K, lysine residue; S, serine residue. 
From ref 8: Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8:355-367.
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KDM3A (JHDM2a), can demethylate 1 or 2 methyl
groups on H3K9, requiring a distinct demethylase, eg,
KDM4D (JMJD2D) to fully demethylate the trimethy-
lated state. Thus, large complexes of enzymes are
required to move between the unmethylated and fully
trimethylated states. Proper balance of histone methy-
lation has already been strongly implicated in normal
brain function, as the HDM, KMT5C (SMCX), controls
dendritic spine density and is mutated in patients with
mental retardation.
22,23
DNA methylation
DNA methylation refers to the enzymatic methylation
of cytosine bases, a fundamental cellular process
required for development, tissue-specific gene expres-
sion, X-inactivation, and genetic imprinting, to name a
few examples.
24 DNA methylation is thought to repress
gene expression by interfering with the binding of tran-
scription factors to their target sequences or by initiat-
ing the recruitment of corepressors. For example, the
cAMP-response element (CRE) contains a cytosine-
guanine dinucleotide in the middle of its consensus
sequence, which, when methylated, prevents the tran-
scription factor CRE-binding protein (CREB) from
binding.
25Thus, for genes at which CREB is necessary to
initiate transcription, methylation at this site is repres-
sive. Methylated DNA can also recruit methyl-binding
domain-containing proteins, such as MeCP2, which can
then recruit and stabilize transcriptional corepressors
such as HDACs on specific gene promoters. Mutations
in MeCP2 cause the autistic spectrum disorder, Rett syn-
drome, illustrating the importance of DNA methylation
in normal brain development.
26 While there is a strong
correlation between methylated DNA and repressed
gene activity, recent studies of MeCP2 indicate it may
also serve to activate gene activity under some circum-
stances,
27 suggesting that the context in which DNA
methylation occurs is an important factor in its ultimate
effect on transcription. 
There are three known enzymes which catalyze DNA
cytosine methylation: DNMT1, DNMT3a, and DNMT3b.
DMNT2 was recently shown to methylate RNA rather
than DNA.
28Together, these enzymes establish and main-
tain the unique methylation patterns that exist within
each cell type. While the regulation of these enzymes in
brain remains unclear, pharmacological inhibition of
DNA methylation in the brain in vivo results in rapid
demethylation of specific gene targets and severe deficits
in learning and memory.
29The mechanism by which this
occurs, however, remains unclear because, unlike other
chromatin modifications, the existence of DNA demethy-
lases remains controversial.
30 Nevertheless, regulation of
DNA methylation by environmental stimuli remains an
attractive mediator of long-lasting changes in transcrip-
tion in adult neurons. 
Epigenetic mechanisms in drug addiction
Drug addiction is a chronic relapsing disorder where
motivation to seek and take drugs of abuse becomes
compulsive and pathological.
31 The process by which
repeated drug experimentation transitions into a chron-
ically addicted state is the focus of intense research, as
clues into these mechanisms may help better manage or
perhaps fully treat addicted patients. Another avenue of
intense research focuses on the mechanisms driving drug
relapse, which occurs even after long periods of drug
abstinence and is a major clinical challenge for success-
ful treatment. The exciting new possibility that drug-
induced alterations in chromatin structure may con-
tribute to long-lasting behavioral changes provides a
new avenue for novel therapeutics that improve drug
rehabilitation. 
The first studies to implicate changes in chromatin struc-
ture in responses to drugs of abuse found that acute
administration of cocaine rapidly increased histone H4
acetylation on the immediate early genes c-fos and fosB
in striatum,
32 two genes known to play a critical role in
cocaine-related behaviors.
33The histone acetyltransferase
CBP appears to be required for the drug-induced acety-
lation of the fosB promoter, and probably many other,
yet to be identified genes as well.
34 Interestingly, despite
several control gene promoters where acute cocaine does
not affect histone acetylation, an acute cocaine dose
increases total levels of histone H4 acetylation, and his-
tone H3 phosphoacetylation in striatum, as measured by
Western blotting.
19,32 These global increases in histone
acetylation, which are also observed in response to envi-
ronmental enrichment and tests of learning and mem-
ory,
35,36 may be accounted for by high levels of acetylation
on specific subsets of genes. This is likely, as global
increases in histone K9 methylation, a repressive histone
modification, are also observed after cocaine exposure
37
and appear to occur on unique subsets of genes.
38
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cocaine exposure are hyperacetylated for days to weeks
after the last drug exposure (Figure 2). For example, the
expression of cdk5 (cyclin-dependent kinase 5), bdnf
(brain derived neurotrophic factor),
32 npy (neuropeptide
Y),
39 and sirt1 and sirt2 (two subtypes of sirtuins), among
many other genes,
38 were found to be upregulated after
chronic cocaine administration and their gene promot-
ers hyperacetylated, while egr-1 (early growth response
1) was found to be downregulated and hypoacetylated
after cocaine withdrawal.
39 Moreover, altered expression
of each of these genes has been shown to contribute to
the addiction behavioral phenotype. These findings sug-
gest a role of histone acetylation in the maintenance of
gene expression involved in drug addiction, including
drug withdrawal and relapse. 
Cocaine-induced alterations in chromatin structure in
the nucleus accumbens (NAc), the ventral portion of
striatum heavily implicated as a brain reward region,
have been shown to regulate behavioral responses to
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Figure 2. Regulation of chromatin structure by drugs of abuse. Drug-induced signaling events are depicted for psychostimulants such as cocaine and
amphetamine. These drugs increase cAMP levels in striatum, which activates protein kinase A (PKA) and leads to phosphorylation of its tar-
gets. This includes the cAMP response element binding protein (CREB), the phosphorylation of which induces its association with the histone
acetyltransferase, CREB binding protein (CBP) to acetylate histones and facilitate gene activation. This is known to occur on many genes includ-
ing fosB and c-fos in response to psychostimulant exposure. FosB is also upregulated by chronic psychostimulant treatments, and is known
to activate certain genes (eg, cdk5) and repress others (eg, c-fos) where it recruits HDAC1 as a corepressor. This repression of c-fos also involves
increased repressive histone methylation, which is thought to occur via the induction of specific histone methyltransferases (HMTs). In addi-
tion, cocaine regulates the HMT, KMT1C/G9a, which alters histone H3 methylation on K9. It is not yet known how cocaine regulates histone
demethylases (HDM) or DNA methyltransferases (DNMTs). Cocaine also activates the mitogen activated protein kinase (MAPK) cascade, which
through MSK1 can phosphorylate CREB and histone H3 at serine 10. Cocaine promotes H3 phosphorylation via a distinct pathway, whereby
PKA activates protein phosphatase 2A, leading to the dephosphorylation of serine 97 of DARPP32. This causes DARPP32 to accumulate in
the nucleus and inhibit protein phosphatase-1 (PP1) which normally dephosphorylates H3. Chronic exposure to psychostimulants increases
glutamatergic stignaling from the prefrontal cortex to the NAc. Glutamatergic signaling elevates Ca2+ levels in NAc postsynaptic elements
where it activates CaMK (calcium/calmodulin protein kinases) signaling, which, in addition to phosphorylating CREB, also phosphorylates
HDAC5. This results in nuclear export of HDAC5 and increased histone acetylation on its target genes (eg, NK1R [NK1 or substance P recep-
tor]). 
From ref 8: Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8:355-367.
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the NAc, which increases histone acetylation in this
brain region, significantly potentiates the locomotor-acti-
vating and rewarding responses to cocaine.
32,40,41
Conversely, reducing histone acetylation by overex-
pressing certain HDACs, or knockdown of the HAT,
CBP, results in less sensitivity to cocaine.
32,34,40Two reports
have extended these findings in rat models of cocaine
self-administration, where animals are trained to press
levers to receive the drug. Interestingly, delivery of the
HDAC inhibitor, sodium butyrate, potentiates drug-tak-
ing
42 while delivery of the HDAC inhibitor, trichostatin
A, attenuates it.
43 The explanation for these different
observations is unclear, but it may involve experimental
differences with the self-administration paradigm or the
HDAC inhibitor used.
Cocaine alters histone acetylation through many
enzymes in the NAc, but one particular HDAC, HDAC5,
responds uniquely to chronic cocaine administration,
raising the interesting possibility that this HDAC is
involved in the behavioral transitions which occur
between acute and chronic cocaine exposure (eg, drug
experimentation to compulsive drug use). Chronic
cocaine administration increases the phosphorylation of
HDAC5 and shuttles it out of the nucleus, permitting
hyperacetylation of histones at target genes for HDAC5
(Figure 2).
40This phosphorylation reaction may be medi-
ated by Ca
2+/calmodulin-dependent protein kinase II
(CaMKII), since ex vivo inhibition of CaMKII reduces
the activity-induced phosphorylation of HDAC5.
Consistent with its regulation by cocaine, mice deficient
for HDAC5 display normal rewarding responses to ini-
tial cocaine exposures, but become hypersensitive when
treated with a chronic course of cocaine.
40 Thus, phar-
macological and genetic manipulations that increase his-
tone acetylation appear to potentiate behavioral
responses to cocaine and suggest that altered histone
acetylation may contribute to establishment of an
addicted state. 
Histone H3 phosphorylation and phosphoacetylation
also appear to play key roles in drug-regulated behav-
iors. Global levels of histone H3 phosphorylation at ser-
ine 10 are induced by acute cocaine in striatum, a
process which requires the kinase MSK1.
19,32 The func-
tion of MSK1 is behaviorally important, as mice lacking
this kinase have attenuated locomotor responses to
cocaine. Cocaine-induced inhibition of protein phos-
phatase-1 also plays an important role in H3 phospho-
rylation in striatum (Figure 2). Dopamine D1 receptor
activation alters the phosphorylation of dopamine-reg-
ulated and cyclic-AMP-regulated phosphoprotein of
32kD (DARPP-32) at particular serine residues; the pro-
tein then accumulates in the nucleus to inhibit protein
phosphatase-1 from dephosphorylating histone H3.
20The
simultaneous activation of an H3 kinase and inhibition
of an H3 phosphatase results in the robust increase in
H3 phosphorylation after acute cocaine exposure. The
genes at which histone phosphorylation is occurring in
response to cocaine remain poorly defined with an
exception of c-fos, where dramatic histone phosphory-
lation occurs in conjunction with acetylation (phospho-
acetylation). 
As mentioned earlier, global histone methylation of
H3K9 is also regulated by cocaine and, in turn, alters
behavioral responses to the drug. For example, inhibi-
tion of a particular H3K9 histone methyltransferase,
KMT1C (G9a), whose expression is regulated in the
NAc by chronic cocaine administration, potentiates
behavioral responses to the drug.
37 These findings are
consistent with histone acetylation findings, since inhi-
bition of H3K9 methylation would also be expected to
enhance gene activity. Together, these data suggest that,
in general, increases in gene expression potentiate
behavioral sensitivity to drugs of abuse. As well,
advances are being made in identifying the individual
gene promoters where chronic cocaine induces alter-
ations in H3K9 methylation and thereby regulates gene
expression in the NAc.
37
Overall, these findings implicate changes in histone
acetylation, phosphorylation, and methylation in medi-
ating expression changes in specific sets of genes that are
crucial for controlling behavioral responses to drugs of
abuse. 
Epigenetic mechanisms in depression
Depression is a chronic disorder characterized by many
debilitating symptoms including dysphoria, anhedonia,
sleep disturbances, and weight changes. Most people
diagnosed with depression are prescribed some type of
antidepressant medication, of which selective serotonin
reuptake inhibitors (SSRIs) or mixed serotonin-norepi-
nephrine reuptake inhibitors (SNRIs) are the most com-
mon. Unfortunately, less than 50% of patients exhibit a
complete response to SSRIs, SNRIs, or related antide-
pressants, thus leaving a substantial portion of depressed
Translational research
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patients with a chronic syndrome for which few effective
clinical alternatives are available. Psychiatric research is
thus focused on identifying new mechanisms that are
involved in the pathogenesis and maintenance of depres-
sion, which may serve as novel targets for more effective
therapeutics.
One of the most challenging obstacles for depression
research has been the development of an animal model
that accurately recapitulates human depression. While no
model can effectively model all aspects of human depres-
sion (eg, suicide), some of the major symptoms such as
anhedonia and sleep and weight disturbances, and their
reversal by antidepressant treatment, can be studied in
rodents. The pathogenesis of depressed-like states is typ-
ically modeled in rodents by chronic exposure to stress.
44
One such model, chronic social defeat stress, involves the
repeated exposure of an experimental mouse to a series
of aggressive mice over 10 days. Each day the stress
begins as a brief physical encounter (typically 5 to 10
minutes) followed by a full day of sensory contact (eg,
smell, sight) as the mice are separated by a screen. After
10 days of social defeat, the experimental mice develop
a chronic syndrome (lasting more than a month) that is
characterized by anhedonia, anxiety-like symptoms,
weight loss, and loss of interest in social interaction.
Importantly, SSRIs or SNRIs reverse most of these
behavioral end points, making chronic social defeat stress
an attractive model in which to study the molecular adap-
tations associated with a depressed-like state and those
involved with antidepressant action.
45,46
Brain derived neurotrophic factor (BDNF) plays a crit-
ical role in the development of the social defeat pheno-
type and its reversal by antidepressant treatment. It was
observed that BDNF in the hippocampus is downregu-
lated for at least 1 month after chronic social defeat
stress, and that chronic antidepressant treatment
reversed this downregulation.
46 A mechanism for this
long-lasting regulation of gene expression was identified
as methylation of H3K27, a repressive histone modifi-
cation, that remains hypermethylated on the bdnf pro-
moter within hippocampus for at least a month after
defeat stress. While chronic antidepressant treatment of
mice exposed to chronic social defeat ameliorates many
of the behavioral deficits and restores bdnf mRNA to
normal levels, H3K27 remains hypermethylated. The
maintenance of H3K27 methylation even after chronic
antidepressant treatment suggests that BDNF expres-
sion might revert to a repressed state if drug adminis-
tration were stopped. This novel epigenetic mechanism,
which was proposed as a form of “molecular scar,” may
describe a potential mechanism by which the symptoms
of depressed patients reappear after cessation of anti-
depressant treatment, however, this remains speculative
and further research is needed. 
The recovery of bdnf expression after antidepressant
treatment is likely mediated by the antidepressant-
induced increase in histone H3K4 methylation and H3
polyacetylation in hippocampus, which are associated
with gene activation.
46 Interestingly, tranylcypromine,
which inhibits monoamine oxidases and is used as an
antidepressant, is actually a much stronger inhibitor of
the histone H3K4 demethylase KMT1A (formerly,
LSD1) than it is of either monamine oxidase A or B.
47
Thus, it will be interesting to determine whether any of
the antidepressant properties of tranylcypromine derive
from its blockade of KMT1A and the subsequent facili-
tation of H3K4 methylation. Arguing against this inter-
pretation is the knowledge that several structurally unre-
lated monoamine oxidase inhibitors, which have not
been shown to inhibit histone demethylases, are still
effective antidepressants.
The increase in H3 acetylation by antidepressant treat-
ment suggested that HDAC inhibitors may also have
antidepressant-like effects. Indeed, in both the chronic
social defeat model and in the forced swim test, HDAC
inhibitors demonstrated antidepressant-like prosperi-
ties.
46,48 This was especially apparent when an HDAC
inhibitor was administered in addition to an SSRI, flu-
oxetine. While these inhibitors target numerous HDACs,
one specific isoform, HDAC5, stood out because it was
oppositely regulated by stress and antidepressant treat-
ment.
46 Indeed, overexpression of HDAC5 in the hip-
pocampus blocks the behavioral effects of chronic anti-
depressant treatment, suggesting that increased histone
acetylation on the bdnf promoter is a key mechanism to
overcome the repressive effects of H3K27 methylation.
Another intriguing aspect of chronic social defeat stress
is that the severity of the depression-like phenotype
varies within a cohort of inbred (ie, virtually genetically
identical) mice. It was observed that mice susceptible to
defeat stress show significantly higher firing rates of
dopaminergic neurons in the ventral tegmental area
(VTA) after stress exposure compared with resilient
mice. These resilient mice had normal VTA firing rates
because of a stress-induced upregulation of potassium
channels in this brain region. Why do certain mice
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while others fail to do this and become “depressed?”
Perhaps an epigenetic mechanism is involved in altering
the promoters of certain potassium channels to ulti-
mately determine if the gene will be induced in response
to chronic stress. If so, which life experiences trigger
these chromatin remodeling events? These are impor-
tant questions that may shed fundamentally new light
onto an extraordinarily complex syndrome, and provide
new avenues for the development of more effective anti-
depressants. 
Another important epigenetic mechanism that may con-
tribute to long-lasting changes in neural function and
behavior is DNA methylation. Early insight into the role
of DNA methylation in behavior followed from studies
of maternal care that clearly demonstrate an experience-
dependent rather than genetic basis for how rats treat
their offspring. Rats that receive poor maternal care as
pups grow up to become poor mothers to their pups. In
addition to becoming poor mothers, these rats also
develop long-lasting heightened anxiety and stress
responses. Meaney and colleagues identified a region of
the glucocorticoid receptor (GR) gene, which was hyper-
methylated throughout adulthood in rats who received
poor maternal care. Treatment with an HDAC inhibitor
not only reduced DNA methylation on the GR receptor
gene but also improved anxiety and stress responses in
these rats.
49 More recently, these studies have been trans-
lated from rats into humans by studying the hippocam-
pus of patients who committed suicide with or without a
history of child abuse. In patients with a history of child
abuse, it was observed that DNA methylation on the GR
gene promoter was significantly higher, while GR mRNA
expression was significantly lower than patients with no
history of child abuse.
50While these data do not demon-
strate causation, they are among the best evidence to
date implicating epigenetic mechanisms in anxiety and
stress and suggest that DNA methylation at the GR gene
promoter (and probably other genes) in both rats and
humans may contribute to this phenomenon. 
Taken together, these studies demonstrate that chro-
matin structure is an important substrate for long-last-
ing changes in behavioral responses to stress and anti-
depressant treatments. While the precise signaling
mechanisms by which environmental stresses converge
on chromatin are still under investigation (eg, Figure 2),
these early studies suggest the exciting possibility that
pharmacological manipulation of chromatin remodeling
pathways could be a novel approach to new antidepres-
sant development. 
Concluding remarks
Chromatin structure is emerging as a key substrate in
the pathogenesis and maintenance of chronic psychiatric
illnesses. This is important because novel therapeutics
could target chromatin remodeling enzymes or chro-
matin itself to ultimately block or even reverse, for
example, a chronically addicted or depressed state.
Ultimately though, the key function of chromatin
remodeling is to alter the transcription or the transcrip-
tional potential of genes which eventually affect neural
function, so any study of chromatin regulation is, in the-
ory, inexorably linked with the study of the underlying
gene activity. While extremely exciting, epigenetic
research in psychiatry is still in its infancy, and far more
research is needed to identify both the dysregulated
genes and chromatin modifications responsible for indi-
vidual psychiatric diseases. Fortunately, new advances in
high-throughput sequencing are enabling such charac-
terization of chromatin regulation and gene expression,
genome-wide, at an incredible rate and resolution.
Armed with these and other new research tools, epige-
netic research in psychiatry is progressing at a spectacu-
lar speed, and may soon prove to be a major avenue for
novel therapeutics. ❏
Acknowledgments: Preparation of this review was supported by grants
from NIDA and NIMH, and the Medical Scientist Training Program at UT
Southwestern Medical Center. Parts of this review were based on ref 8 and
ref 51 with permission. The authors declare no conflicts of interest.
Translational research
266
REFERENCES
1. Bird A. Perceptions of epigenetics. Nature. 2007;447:396-398.
2. Surani MA, Hayashi K, Hajkova P. Genetic and epigenetic regulators of
pluripotency. Cell. 2007;128:747-762.
3. Luger K, Richmond TJ. The histone tails of the nucleosome. Curr Opin
Genet Dev. 1998;8:140-146.
4. Felsenfeld G, Groudine M. Controlling the double helix. Nature.
2003;421:448-453.
5. Li B, Carey M, Workman JL. The role of chromatin during transcription.
Cell. 2007;128:707-719.
6. Kouzarides T. Chromatin modifications and their function. Cell.
2007;128:693-705.
7. Strahl BD, Allis CD. The language of covalent histone modifications.
Nature. 2000;403:41-45.
8. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psy-
chiatric disorders. Nat Rev Neurosci. 2007;8:355-367.
9. Pokholok DK, Harbison CT, Levine S, et al. Genome-wide map of nucle-
osome acetylation and methylation in yeast. Cell. 2005;122:517-527.
PAGES_10_AG_019_BA.qxd:DCNS#42  30/08/09  1:25  Page 266Chromatin regulation in drug addiction and depression - Renthal and Nestler Dialogues in Clinical Neuroscience - Vol 11 . No. 3 . 2009
267
Regulación de la cromatina en la adicción a
drogas y en la depresión
Las alteraciones en la expresión génica están impli-
cadas en la patogénesis de varios trastornos neu-
ropsiquiátricos, incluyendo la adicción a drogas y la
depresión. Existe una evidencia creciente que indica
que los cambios en la expresión génica en las neu-
ronas, en el contexto de modelos animales de adic-
ción y depresión, están mediados en parte por
mecanismos epigenéticos que alteran la estructura
de la cromatina de genes promotores específicos.
Esta revisión discute hallazgos recientes que pro-
vienen de aproximaciones conductuales, molecula-
res y bioinformáticas los cuales están siendo utili-
zados para comprender la compleja regulación
epigenética de la expresión génica en el cerebro
por las drogas de abuso y por el estrés. Estos avan-
ces prometen establecer nuevos caminos para mejo-
res tratamientos de estos trastornos.   
Régulation de la chromatine dans la 
toxicomanie et la dépression
Des modifications de l’expression génique sont
impliquées dans la pathogenèse de plusieurs mala-
dies neuropsychiatriques, y compris la toxicomanie
et la dépression. Des modèles animaux de ces
pathologies montrent de plus en plus que des varia-
tions de l’expression des gènes dans les neurones
sont transmises en partie par des mécanismes épi-
génétiques qui changent la structure de la chro-
matine sur les promoteurs spécifiques des gènes.
Cet article analyse les résultats récents des
approches comportementales, moléculaires et bio-
informatiques utilisées pour comprendre la régula-
tion épigénétique complexe de l’expression
génique dans le cerveau par l’abus de substances et
par le stress. Ces avancées ouvrent de nouvelles
voies pour mieux traiter ces maladies.
10. Doi M, Hirayama J, Sassone-Corsi P. Circadian regulator CLOCK is a his-
tone acetyltransferase. Cell. 2006;125:497-508.
11. Kawasaki H, Schiltz L, Chiu R, et al. ATF-2 has intrinsic histone acetyl-
transferase activity which is modulated by phosphorylation. Nature.
2000;405:195-200.
12. Chawla S, Vanhoutte P, Arnold FJ, Huang CL, Bading H. Neuronal activ-
ity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J
Neurochem. 2003;85:151-159.
13. Fischle W, Dequiedt F, Hendzel MJ, et al. Enzymatic activity associated
with class II HDACs is dependent on a multiprotein complex containing
HDAC3 and SMRT/N-CoR. Mol Cell. 2002;9:45-57.
14. Lahm A, Paolini C, Pallaoro M, et al. Unraveling the hidden catalytic activ-
ity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A
2007;104:17335-17340.
15. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bac-
teria and yeast to mice and men. Nat Rev Mol Cell. Biol 2008;9:206-218.
16. Haigis MC, Guarente LP. Mammalian sirtuins--emerging roles in physi-
ology, aging, and calorie restriction. Genes Dev. 2006;20:2913-2921.
17. Brami-Cherrier K, Lavaur J, Pages C, Arthur JS, Caboche J. Glutamate
induces histone H3 phosphorylation but not acetylation in striatal neurons:
role of mitogen- and stress-activated kinase-1. J Neurochem. 2007;101:697-708.
18. Li J, Guo Y, Schroeder FA, et al. Dopamine D2-like antagonists induce
chromatin remodeling in striatal neurons through cyclic AMP-protein kinase
A and NMDA receptor signaling. J Neurochem. 2004;90:1117-1131.
19. Brami-Cherrier K, Valjent E, Herve D, et al. Parsing molecular and behav-
ioral effects of cocaine in mitogen- and stress-activated protein kinase-1-
deficient mice. J Neurosci. 2005;25:11444-11454.
20. Stipanovich A, Valjent E, Matamales M, et al. A phosphatase cascade by
which rewarding stimuli control nucleosomal response. Nature. 2008;453:879-
884.
21. Vakoc CR, Mandat SA, Olenchock BA, Blobel GA. Histone H3 lysine 9
methylation and HP1gamma are associated with transcription elongation
through mammalian chromatin. Mol Cell. 2005;19:381-391.
22. Iwase S, Lan F, Bayliss P, et al. The X-linked mental retardation gene
SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell.
2007;128:1077-1088.
23. Jensen LR, Amende M, Gurok U, et al. Mutations in the JARID1C gene,
which is involved in transcriptional regulation and chromatin remodeling,
cause X-linked mental retardation. Am J Hum Genet. 2005;76:227-236.
24. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights
from epigenomics. Nat Rev Genet. 2008;9:465-476.
25. Zhang X, Odom DT, Koo SH, et al. Genome-wide analysis of cAMP-
response element binding protein occupancy, phosphorylation, and target
gene activation in human tissues. Proc Natl Acad Sci U S A. 2005;102:4459-
4464.
26. Ramocki MB, Zoghbi HY. Failure of neuronal homeostasis results in com-
mon neuropsychiatric phenotypes. Nature. 2008;455:912-918.
27. Chahrour M, Jung SY, Shaw C, et al. MeCP2, a key contributor to neu-
rological disease, activates and represses transcription. Science. 2008;320:1224-
1229.
28. Goll MG, Kirpekar F, Maggert KA, et al. Methylation of tRNAAsp by the
DNA methyltransferase homolog Dnmt2. Science. 2006;311:395-398.
29. Miller CA, Sweatt JD. Covalent modification of DNA regulates memory
formation. Neuron. 2007;53:857-869.
30. Ooi SK, Bestor TH. The colorful history of active DNA demethylation. Cell.
2008;133:1145-1148.
31. Hyman S, Malenka R, Nestler E. Neural mechanisms of addiction: the role
of reward-related learning and memory. Annu Rev Neurosci. 2006;29:565-598.
32. Kumar A, Choi KH, Renthal W, et al. Chromatin remodeling is a key
mechanism underlying cocaine-induced plasticity in striatum. Neuron.
2005;48:303-314.
33. Nestler EJ. Review. Transcriptional mechanisms of addiction: role of
DeltaFosB. Philos Trans R Soc Lond B Biol Sci. 2008;363:3245-3255.
34. Levine AA, Guan Z, Barco A, et al. CREB-binding protein controls response
to cocaine by acetylating histones at the fosB promoter in the mouse stria-
tum. Proc Natl Acad Sci U S A. 2005;102:19186-19191.
35. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learn-
ing and memory is associated with chromatin remodelling. Nature.
2007;447:178-182.
36. Levenson JM, O'Riordan KJ, Brown KD, et al. Regulation of histone acety-
lation during memory formation in the hippocampus. J Biol Chem.
2004;279:40545-40559.
PAGES_10_AG_019_BA.qxd:DCNS#42  30/08/09  1:25  Page 26737. Maze I, Covington HE, 3rd, Laplant Q, et al. Histone methylation in the
nucleus accumbens controls behavioral responses to cocaine. Soc Neurosci
Abs. In press.
38. Renthal W, Kumar A, Xiao G, et al. Genome wide analysis of chromatin
regulation by cocaine reveals a novel role for sirtuins. Neuron. 2009;62:335-
348.
39. Freeman WM, Patel KM, Brucklacher RM, et al. Persistent alterations in
mesolimbic gene expression with abstinence from cocaine self-administra-
tion. Neuropsychopharmacology. 2008;33:1807-1817.
40. Renthal W, Maze I, Krishnan V, et al. Histone deacetylase 5 epigeneti-
cally controls behavioral adaptations to chronic emotional stimuli. Neuron.
2007;56:517-529.
41. Schroeder FA, Penta KL, Matevossian A, et al. Drug-induced activation
of dopamine D(1) receptor signaling and inhibition of class I/II histone
deacetylase induce chromatin remodeling in reward circuitry and modulate
cocaine-related behaviors. Neuropsychopharmacology. 2008;33:2981-2992.
42. Sun J, Wang L, Jiang B, et al. The effects of sodium butyrate, an
inhibitor of histone deacetylase, on the cocaine- and sucrose-maintained
self-administration in rats. Neurosci Lett. 2008;441:72-76.
43. Romieu P, Host L, Gobaille S, et al. Histone deacetylase inhibitors
decrease cocaine but not sucrose self-administration in rats. J Neurosci.
2008;28:9342-9348.
44. Krishnan V, Nestler EJ. The molecular neurobiology of depression.
Nature. 2008;455:894-902.
45. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the
mesolimbic dopamine pathway in social defeat stress. Science. 2006;311:864-
868.
46. Tsankova N, Berton O, Renthal W, et al. Sustained hippocampal chro-
matin regulation in a mouse model of depression and antidepressant
action. Nat Neurosci. 2006;9:519-525.
47. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone
H3 lysine 4 demethylation is a target of nonselective antidepressive med-
ications. Chem Biol. 2006;13:563-567.
48. Schroeder FA, Lin CL, Crusio WE, Akbarian S. Antidepressant-like effects
of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol
Psychiatry. 2007;62:55-64.
49. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming
by maternal behavior. Nat Neurosci. 2004;7:847-854.
50. McGowan PO, Sasaki A, D'Alessio AC, et al. Epigenetic regulation of
the glucocorticoid receptor in human brain associates with childhood abuse.
Nat Neurosci. 2009;12:342-348.
51. Renthal W, Nestler EJ. Epigenetic mechanisms in drug addiction. Trends
Mol Med. 2008;14:341-350.
Translational research
268
PAGES_10_AG_019_BA.qxd:DCNS#42  30/08/09  1:25  Page 268